Trial · NCT01515423
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Open Label Phase | STARTED | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | 1,429 | |
| Open Label Phase | STARTED | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | 0 | |
| Open Label Phase | STARTED | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | 0 | |
| Open Label Phase | COMPLETED | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | 1,016 | |
| Open Label Phase | COMPLETED | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | 0 | |
| Open Label Phase | COMPLETED | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | 0 | |
| Open Label Phase | NOT COMPLETED | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | 413 | |
| Open Label Phase | NOT COMPLETED | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | 0 | |
| Open Label Phase | NOT COMPLETED | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | 0 | |
| DOUBLE BLIND | STARTED | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | 0 | |
| DOUBLE BLIND | STARTED | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | 504 | |
| DOUBLE BLIND | STARTED | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | 512 | |
| DOUBLE BLIND | COMPLETED | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | 0 | |
| DOUBLE BLIND | COMPLETED | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | 422 | |
| DOUBLE BLIND | COMPLETED | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | 420 | |
| DOUBLE BLIND | NOT COMPLETED | Open-Label: Paliperidone Palmitate (PP1M) 1-month Formulation | 0 | |
| DOUBLE BLIND | NOT COMPLETED | Double-Blind: Paliperidone Palmitate(PP3M) 3-month Formulation | 82 | |
| DOUBLE BLIND | NOT COMPLETED | Double-Blind: Paliperidone Palmitate(PP1M) 1-month Formulation | 92 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01515423/flow